Papers - KANAI Yae

ADAM9 is over-expressed in human ovarian clear cell carcinomas and suppresses cisplatin-induced cell death.

Ueno M, Shiomi T, Mochizuki S, Chijiiwa M, Shimoda M, Kanai Y, Kataoka F, Hirasawa A, Susumu N, Aoki D, Okada Y.

Cancer Sci (Cancer Science)  109 ( 2 ) 471 - 482 2018

Research paper (scientific journal), Single Work, Accepted,  ISSN  13479032

　View Summary

© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. ADAMs (a disintegrin and metalloproteinases) are involved in various biological events such as cell adhesion, migration and invasion, membrane protein shedding and proteolysis. However, there have been no systematic studies on the expression of ADAMs in human ovarian carcinomas. We therefore examined mRNA expression of all the proteolytic ADAM species including ADAM8, 9, 10, 12, 15, 17, 19, 20, 21, 28, 30, 33 and ADAMDEC1 in human ovarian carcinomas, and found that prototype membrane-anchored ADAM9m, but not secreted isoform ADAM9s, is significantly over-expressed in carcinomas than in control non-neoplastic ovarian tissue. Among the histological subtypes of serous, endometrioid, mucinous and clear cell carcinomas, ADAM9m expression was highest in clear cell carcinomas. Immunohistochemistry showed that all the clear cell carcinoma samples displayed ADAM9m primarily on the carcinoma cell membrane. By immunoblotting, ADAM9m was detected mainly in an active form in the clear cell carcinoma tissues. When two clear cell carcinoma cell lines (RMG-I and TOV21G cell

• Access to Document (DOI)

511 IDENTIFICATION OF CYP2A6 GENE RELATED TO INVASIVE BLADDER CARCINOGENESIS

K Kanemoto, K Fukuta, K Yamada, N Kawai, K Tozawa, Y Kanai, ...

JOURNAL OF UROLOGY 200 (3), e208-e208  2018

Somatic mutations in IFN-γ-Signal molecules in human uterine leiomyosarcoma

T Hayashi, T Ichimura, M Kasai, K Sano, S Tonegawa, Y Kanai, ...

 2018

Somatic mutations in IFN-γ-Signal molecules in human uterine leiomyosarcoma

T Hayashi, T Ichimura, M Kasai, K Sano, S Tonegawa, Y Kanai, ...

 2018

Somatic mutations in IFN-γ-Signal molecules in human uterine leiomyosarcoma

T Hayashi, T Ichimura, M Kasai, K Sano, S Tonegawa, Y Kanai, ...

 2018

Risk estimation for hepatocellular carcinoma by DNA methylation analysis using high performance liquid chromatography

E Sunamura, T Yotani, F Arai, Y Tian, A Skeda, H Ojima, T Yoshida, ...

CANCER SCIENCE 109, 243-244  2018

Risk estimation for hepatocellular carcinoma by DNA methylation analysis using high performance liquid chromatography

E Sunamura, T Yotani, F Arai, Y Tian, A Skeda, H Ojima, T Yoshida, ...

CANCER SCIENCE 109, 243-244  2018

Risk estimation for hepatocellular carcinoma by DNA methylation analysis using high performance liquid chromatography

E Sunamura, T Yotani, F Arai, Y Tian, A Skeda, H Ojima, T Yoshida, ...

CANCER SCIENCE 109, 243-244  2018

Risk estimation for hepatocellular carcinoma by DNA methylation analysis using high performance liquid chromatography

E Sunamura, T Yotani, F Arai, Y Tian, A Skeda, H Ojima, T Yoshida, ...

CANCER SCIENCE 109, 243-244  2018

Patient Background and Responses in Providing Informed Consent for the National Cancer Center Biobank Project.

T Yamane, S Yamagami, N Yamashita, T Yoshida, K Tobinai, Y Kanai, ...

CANCER SCIENCE 109, 789-789  2018

Patient Background and Responses in Providing Informed Consent for the National Cancer Center Biobank Project.

T Yamane, S Yamagami, N Yamashita, T Yoshida, K Tobinai, Y Kanai, ...

CANCER SCIENCE 109, 789-789  2018

Patient Background and Responses in Providing Informed Consent for the National Cancer Center Biobank Project.

T Yamane, S Yamagami, N Yamashita, T Yoshida, K Tobinai, Y Kanai, ...

CANCER SCIENCE 109, 789-789  2018

Patient Background and Responses in Providing Informed Consent for the National Cancer Center Biobank Project.

T Yamane, S Yamagami, N Yamashita, T Yoshida, K Tobinai, Y Kanai, ...

CANCER SCIENCE 109, 789-789  2018

Novel method for DNA methylation analysis using high‐performance liquid chromatography and its clinical application

T Yotani, Y Yamada, E Arai, Y Tian, M Gotoh, M Komiyama, H Fujimoto, ...

Cancer science 109 (5), 1690-1700  2018

Novel method for DNA methylation analysis using high‐performance liquid chromatography and its clinical application

T Yotani, Y Yamada, E Arai, Y Tian, M Gotoh, M Komiyama, H Fujimoto, ...

Cancer science 109 (5), 1690-1700  2018

Novel method for DNA methylation analysis using high‐performance liquid chromatography and its clinical application

T Yotani, Y Yamada, E Arai, Y Tian, M Gotoh, M Komiyama, H Fujimoto, ...

Cancer science 109 (5), 1690-1700  2018

Method for determining prognosis of renal cell carcinoma

Y Kanai, E Arai, Y Nemoto, T Yotani

US Patent App. 16/000,532  2018

Method for determining prognosis of renal cell carcinoma

Y Kanai, E Arai, Y Nemoto, T Yotani

US Patent App. 16/000,532  2018

Method for determining prognosis of renal cell carcinoma

Y Kanai, E Arai, Y Nemoto, T Yotani

US Patent App. 16/000,532  2018

Method for determining prognosis of renal cell carcinoma

Y Kanai, E Arai, Y Nemoto, T Yotani

US Patent App. 16/000,532  2018